Monitor the December 3, 2026 special meeting for stockholder approval of the merger and reverse stock split. The key risk is failure to obtain required approvals, which would likely lead to a significant decline in FULC's stock price and potential liquidation. If approved, the combined company's value will depend on Slate's clinical progress with SLTE-1009.
Price Chart
How similar events traded
Executive Summary
Fulcrum Therapeutics filed Amendment No. 3 to its S-4 registration statement for the proposed reverse merger with Slate Medicines. Under the merger agreement, pre-merger Fulcrum stockholders are expected to own approximately 5.0% of the combined company on a fully diluted basis, while pre-merger Slate stockholders (excluding concurrent investment investors) will own approximately 55.9% and concurrent investment investors will own approximately 39.1%. Fulcrum stockholders will receive a pre-closing special cash dividend estimated at approximately $270 million. The merger is subject to stockholder approval at a special meeting scheduled for December 3, 2026.
Key Facts
- Fulcrum and Slate entered into a merger agreement on August 16, 2026; the transaction is structured as a reverse merger with Slate as the accounting acquirer.
- Pre-merger Fulcrum stockholders are expected to own approximately 5.0% of the combined company on a fully diluted basis.
- Pre-merger Slate stockholders (excluding concurrent investment investors) are expected to own approximately 55.9%.
- Investors in the Slate Concurrent Investment (approximately $245 million) are expected to own approximately 39.1%.
- Fulcrum stockholders will receive a pre-closing special cash dividend estimated at approximately $270 million.
- The combined company will be renamed Slate Medicines, Inc. and trade under the symbol SLTE on Nasdaq.
- All six members of the combined company's board of directors will be Slate designees; Slate's executive team will lead the combined company.
- Fulcrum has discontinued its pociredir program and reduced its workforce by approximately 85% to nine employees.
- Slate's lead candidate SLTE-1009 (anti-PACAP/VIP monoclonal antibody for migraine) initiated a Phase 1 trial in Australia in August 2026.
- Fulcrum's net loss was $74.9 million for FY2025 and $45.1 million for H1 2026; accumulated deficit was $639.3 million as of June 30, 2026.
- Slate's net loss was $4.5 million for Q2 2026 and $1.3 million for FY2025; accumulated deficit was $17.1 million as of June 30, 2026.
- Fulcrum had 76,381,948 shares outstanding as of the October 28, 2026 record date.
- Fulcrum's closing price on August 14, 2026 (last trading day before merger announcement) was $3.74 per share.
- Fulcrum's market cap at analysis time was $288 million.
- The merger is expected to close in Q4 2026, subject to stockholder and regulatory approvals.
Financial Impact
Pre-merger Fulcrum stockholders to own ~5% of combined company (~$288M market cap implies ~$14.4M value) plus ~$270M special cash dividend. Slate valued at $350M exclusive of $245M concurrent investment.
Risk Factors
- Failure to obtain stockholder approval for the merger and reverse stock split could prevent the transaction from closing.
- Nasdaq listing approval for the combined company is a condition to closing and may not be obtained.
- Fulcrum's existing stockholders face extreme dilution, retaining only ~5% of the combined company.
- Slate's lead candidate SLTE-1009 is in early-stage clinical development with no human efficacy data and faces competition from established CGRP-targeted therapies.
- If the merger fails, Fulcrum may pursue liquidation, with uncertain cash distributions to stockholders.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-4/A Filing (Primary) | 0001193125-26-444432 |
| Document: d127837dex231.htm | 0001193125-26-444432 |
| Document: d127837dex232.htm | 0001193125-26-444432 |
| Document: 0001193125-26-444432-index-headers.html | 0001193125-26-444432 |
| Document: 0001193125-26-444432-index.html | 0001193125-26-444432 |
| Document: 0001193125-26-444432.txt | 0001193125-26-444432 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 3, 2026 1d ago | S-4/A | $3.72 | awaiting T+1 | awaiting T+1 | $3.76 (+0.94%) |
Oct 28, 2026 7d ago | SC 13G/A | $3.75 $3.77 | ▲ +0.53% | ▲ +0.92% | $3.76 (+0.13%) |
Oct 27, 2026 7d ago | SC 13G/A | $3.75 $3.77 | ▲ +0.53% | ▲ +0.92% | $3.76 (+0.13%) |
Oct 20, 2026 14d ago | S-4/A | $3.70 $3.68 | ▲ +0.54% | ▼ −0.64% | $3.76 (−1.49%) |
Oct 8, 2026 26d ago | S-4/A | $3.77 $3.75 | ▼ −0.53% | ▼ −0.47% | $3.76 (−0.40%) |
Sep 1, 2026 9w ago | S-4 | $3.85 $3.84 | ▲ +0.26% | ▲ +1.31% | $3.76 (+2.47%) |
Aug 17, 2026 11w ago | 425 | $3.84 $3.87 | ▼ −0.78% | ▼ −1.46% | $3.76 (+2.21%) |
Aug 17, 2026 11w ago | 425 | $3.84 $3.87 | ▲ +0.78% | ▲ +1.46% | $3.76 (−2.21%) |
Aug 17, 2026 11w ago | 8-K | $3.84 $3.87 | ▲ +0.78% | ▲ +1.46% | $3.76 (−2.21%) |
Aug 17, 2026 11w ago | Press Release | $3.84 $3.87 | ▲ +0.78% | ▲ +1.46% | $3.76 (−2.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers